Compare CGEN & APYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEN | APYX |
|---|---|---|
| Founded | 1993 | 1982 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 156.7M |
| IPO Year | 2001 | 1995 |
| Metric | CGEN | APYX |
|---|---|---|
| Price | $1.73 | $3.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 203.5K | 117.5K |
| Earning Date | 01-01-0001 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $164.92 | $6.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.13 | $0.83 |
| 52 Week High | $2.38 | $4.50 |
| Indicator | CGEN | APYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 40.31 |
| Support Level | $1.47 | $3.30 |
| Resistance Level | $1.72 | $4.40 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 45.87 | 6.52 |
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.